Gardasil, a cervical cancer vaccine, hits the market

This is indeed an important milestone in the development of strategies to combat cervical abnormalities; the worlds first ever vaccine for cervical cancer, named Gardasil, has made it to the market.

A feather in the cap of Professor Frazer, a scientist in Queens land and the brain behind this vaccine, who has relentlessly worked on this working on it since 1990, is all set to administer the inaugural shot. This vaccine is powerful in containing the spread of sexually transmitted human papilloma virus (HPV), the main reason behind cervical cancer. Further this vaccine will also protect against HPV, which causes genital warts.

An ecstatic Fraser said 'The vaccine will be available from today so if someone turns up at the pharmacy with a script they'll be able to get it. I know there's a large number of people waiting for this particular day to happen because I get phoned up regularly and asked when it was going to occur.'

The Therapeutic Goods Administration (TGA) has permitted the use of this vaccine for boys aged nine to 15 and girls aged nine to 26. This vaccine holds a world of promise, based on the results of the clinical trials, where nearly 20,000 women received 100% protection from cervical cancer and 99% insulation from genital warts.